genital%20herpes
GENITAL HERPES
Genital herpes is a recurrent lifelong disease with no cure, caused by herpes simplex virus (HSV).
HSV-2 is usually the cause but HSV-1 may occur in up to 1/3 of new cases.
HSV-1 tends to cause fewer recurrences & milder disease than HSV-2.
The incubation period is 2 days-2 weeks after exposure.

Genital Herpes Drug Information

Drug Information

Indication: Treatment & prevention of herpes simplex virus infections, genital herpes of skin & mucous membranes &...

Indication: HSV skin infections including initial & recurrent genital herpes labialis.

Indication: Herpes simplex virus infections of skin & mucous membranes including initial & recurrent genital herpe...

Indication: HSV skin infection including genital herpes & herpes labialis.

Indication: Herpes zoster. Accelerates resolution of pain by reducing duration & proportion of patients w/ zoster-asso...

Indication: Promoting resolution of acute clinical manifestations of mucocutaneous HSV infections in immunocompromised pat...

Indication: Herpes simplex skin & mucous membrane infections including initial & recurrent genital herpes. Suppres...

Indication: Treatment & prophylaxis of herpes genitalis, treatment of herpes zoster, herpes simples & varicella (c...

1  /  4
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Pank Jit Sin, 13 May 2020
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier. 
Jairia Dela Cruz, 18 Dec 2020
Rinsing with mouthwash that contains povidone-iodine (PI) or cetylpyridinium chloride (CPC) helps reduce SARS-CoV-2 levels in the saliva of COVID-19 patients, with the effect persisting for up to 6 hours, as shown in a study from Singapore.